Ulcerative Colitis European Registry: A Prospective, Observational, Non-Interventional, Post-Marketing Safety Surveillance Program.
Phase of Trial: Phase IV
Latest Information Update: 06 Jan 2017
At a glance
- Drugs Infliximab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Merck & Co; Schering-Plough
- 08 Nov 2016 Status changed from active, no longer recruiting to completed.
- 11 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Feb 2012 Planned end date changed from 1 Sep 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov.